Vimarsana
Biggest News Aggregation in the World

Page 48 - James Chambers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from James Chambers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In James Chambers Today - Breaking & Trending Today

Council advances new school, downtown committee - Vimarsana News

Council advances new school, downtown committee

Work has yet to start, but Brandon is closer to building its next school after Monday’s city c...

Facebook's Apps Went Down. The World Saw How Much It Runs on Them. - Vimarsana News

Facebook's Apps Went Down. The World Saw How Much It Runs on Them.

The outage disrupted the digital lives of small-business owners, politicians, aid workers and others. But for some, it was a welcome reprieve.

Facebook's apps went down and the world saw how much it runs on them - Vimarsana News

Facebook's apps went down and the world saw how much it runs on them

People in many places discovered that Facebook and its apps had burrowed their way into nearly every facet of existence.

Facebook Outage Shows World Reliance on WhatsApp, Instagram - Vimarsana News

Facebook Outage Shows World Reliance on WhatsApp, Instagram

The outage disrupted the digital lives of small-business owners, politicians, aid workers and others. But for some, it was a welcome reprieve.

Alzheimer's patients are in limbo as hospitals, insurers weigh Aduhelm - Vimarsana News

Alzheimer's patients are in limbo as hospitals, insurers weigh Aduhelm

Adobe For all the explosive controversy over the approval of the first treatment for Alzheimer’s disease in nearly 20 years, hardly any patients have actually gotten it yet. The drug’s eye-popping, $56,000 annual price and questionable benefit to patients have been a shock to the bureaucracy that makes the health care system run — and that’s having a clear effect on uptake. Some analysts estimated last month that fewer than 100 patients were dosed in the first weeks after the therapy was approved, though availability will likely ramp up over the coming months. Though the Food and Drug...